Immix Biopharma Inc Sustainability Reports
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies, specifically chimeric antigen receptor T-cell (CAR-T) treatments, for patients with AL Amyloidosis and other serious diseases.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00HLCWH18
2 reports from 2022 to 2024
Company Profile
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies, specifically chimeric antigen receptor T-cell (CAR-T) treatments, for patients with AL Amyloidosis and other serious diseases.
Reports
2 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
